Colitis, Ulcerative clinical trials
The registry lists 1,853 studies for Colitis, Ulcerative across more than 10 countries. 472 are recruiting or about to start. 1,250 of them are mainly about Colitis, Ulcerative (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-10.
ClinicalTrials.gov finds 1,925 studies for Colitis, Ulcerative. How that becomes 1,853 here
This page counts the studies the registry files under Colitis, Ulcerative, and those it files under no condition that list Colitis, Ulcerativethemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count
- 1,925Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
- −15List Colitis, Ulcerative as a condition, but the registry did not file them under itMost often written as “Pediatric Ulcerative Colitis” (4), “Ulcerative Colitis Chronic Moderate” (3), and “Ulcerative Colitis Chronic Mild” (2). The registry filed them under other conditions only, most often Pediatric ulcerative colitis (6) and Inflammatory Bowel Diseases (5).
- −57Match it another way47 name it in the title, 3 in a keyword, and 7 by a synonym or other text the search reads.
- 1,853The count on this page55 of them list Colitis, Ulcerative in their own words; the registry filed them under no condition.
Get an email when these change. Save the Colitis, Ulcerative studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Status
Who runs them
Takeda (49) · AbbVie (40) · Pfizer (37) · Janssen Research & Development, LLC (23) · Ferring Pharmaceuticals (19) · Bausch Health Americas, Inc. (18) · Assiut University (18) · Bristol-Myers Squibb (17)
What is being tested here
Drugs under test in Colitis, Ulcerative studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Infliximab | 6 | 8 | 25 |
| Mesalamine | 5 | 24 | 48 |
| Vedolizumab | 5 | 13 | 37 |
| Mirikizumab | 4 | 7 | 13 |
| Upadacitinib | 4 | 5 | 8 |
| Etrasimod | 3 | 4 | 11 |
| Risankizumab | 3 | 5 | 8 |
| Duvakitug | 3 | 2 | 5 |
| Vancomycin | 3 | 0 | 4 |
| Tofacitinib | 2 | 5 | 12 |
Drug classes tested here Tyrosine kinase inhibitors (TKIs) 9 open · JAK inhibitors 9 open · Stimulants 3 open · Immune checkpoint inhibitors 2 open · Corticosteroids 1 open
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
The 10 nearest, phase 3 first
- Jan 2027A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis · Phase 3 · Hoffmann-La Roche
- Feb 2027Modafinil for Debilitating Fatigue in Quiescent Inflammatory Bowel Disease MODIFI-IBD Trial) · Phase 3 · Radboud University Medical Center
- Feb 2027A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis · Phase 3 · Janssen Research & Development, LLC
- Mar 2027Evaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis · Phase 3 · Pfizer
- May 2027Comparison of Medical RESCUE Strategies for Patients With Steroid-refractory Acute Severe Ulcerative Colitis · Phase 3 · McMaster University
- Jun 2027Nitazoxanide as Adjunct Therapy in Mild-to-Moderate Ulcerative Colitis · Phase 3 · Tanta University
- Jul 2027A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) · Phase 3 · AbbVie
- Aug 2027A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab · Phase 3 · AbbVie
- Sep 2027Efficacy and Safety of Vedolizumab IV in Chinese Participants With Ulcerative Colitis · Phase 3 · Takeda
- Sep 2027A Long-term Extension Study of Ustekinumab in Pediatric Participants · Phase 3 · Janssen Research & Development, LLC
Who these studies take
Of the 305 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 134 (44%) stop at 75 or younger. 71 (23%) take children under 18. 7 (2%) are for women only and 1 (<1%) for men only; 40 (13%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 52 (17%) | 51 (17%) |
| 18 | 285 (93%) | 280 (92%) |
| 30 | 275 (90%) | 269 (88%) |
| 40 | 272 (89%) | 267 (88%) |
| 50 | 272 (89%) | 266 (87%) |
| 65 | 254 (83%) | 250 (82%) |
| 75 | 225 (74%) | 221 (72%) |
| 85 | 149 (49%) | 145 (48%) |
Across all 1,853 studies, recruiting or not: 43% stop at 75 or younger and 23% at 65; 19% take children; 1% are for women only and 1% for men only; 14% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
How long Colitis, Ulcerative studies take
Of 153 phase 2 interventional studies under Colitis, Ulcerative, half reached primary completion within 28 months of starting, counting those still running.
| Start to primary completion | Every sponsor | Industry | Non-industry |
|---|---|---|---|
| Phase 1 | 13 mo8–26 · 83 studies | 12 mo6–17 · 57 studies | — |
| Phase 2 | 28 mo22–43 · 153 studies | 27 mo21–35 · 109 studies | 43 mo28–62 · 44 studies |
| Phase 3 | 48 mo31–75 · 101 studies | 47 mo31–70 · 87 studies | — |
| Phase 4 | 43 mo25–63 · 63 studies | — | 56 mo33–66 · 48 studies |
| Interventional, no phase | 34 mo16–54 · 236 studies | — | 34 mo16–56 · 225 studies |
| Observational | 47 mo29–90 · 271 studies | 44 mo28–72 · 83 studies | 51 mo30–119 · 188 studies |
Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out
What changed recently
From the registry's own updates since Oct 11, 2026.
Started recruiting9
- Nitazoxanide as Adjunct Therapy in Mild-to-Moderate Ulcerative ColitisNov 9, 2026NCT07820046
- Characterization of Colorectal Dysplasic Lesions and Stratification of Their Evolving Risk in Inflammatory Bowel Disease Patients: a Prospective, Observational and Multicenter StudyNov 6, 2026NCT07719426
- A Sub Study to Investigate the Safety and Tolerability of Aletekitug in Participants With Moderate To Severe Ulcerative ColitisNov 5, 2026NCT07747480
- A Study to Investigate the Safety and Tolerability of Multiple Study Interventions in Participants With Moderate to Severe Ulcerative ColitisOct 28, 2026NCT07747467
- A Study of AC-101 Tablets in Patients With Ulcerative ColitisOct 28, 2026NCT07755241
Show 4 moreShow fewer
- Bacillus Probiotic Spores in Supporting the Treatment of Chronic Inflammatory Bowel DiseaseOct 28, 2026NCT07799428
- Multi-omics Dissection of Gut Microbiome Engraftment During FMTOct 26, 2026NCT06992453
- Estimation of Cardiovascular Risk in Patients With Crohn's Disease and Ulcerative Colitis (PROVACI)Oct 16, 2026NCT07095634
- Prospective Evaluation of Flare Detection in IBD With Digital Biomarkers: Bring Your Own Device StudyOct 13, 2026NCT07647640
Results posted1
Stopped3
- A Study to Investigate the Long-term Safety, Tolerability and Efficacy of Balinatunfib in Participants With Crohn's Disease or Ulcerative Colitis (SPECIFI-IBD-LTS)TerminatedOct 22, 2026NCT07222189
- A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Ulcerative ColitisTerminatedOct 21, 2026NCT06867094
- A Study on Infections in Adults With Ulcerative Colitis/Crohn's DiseaseWithdrawnOct 15, 2026NCT07250815
Newly registered11
- An Open-label, DDI Study to Investigate the Effects of Duvakitug on the PK of Selected Cytochrome P450 SubstratesNov 6, 2026NCT07923383
- Non-Invasive Biomarker Monitoring in UC on BiologicsNov 5, 2026NCT07920367
- Effects of Different Physical Activity Strategies on Disease Activity of IBD PatientsNov 4, 2026NCT07916493
- Specific and Novel Approaches to Care of Inflammatory Bowel Disease During Pregnancy: the PREGO StudyNov 4, 2026NCT07916727
- Safety, Dosage, and Microbiome Engraftment Study of MGT-006 for Ulcerative Colitis (ROOT Study)Nov 3, 2026NCT07913347
Show 6 moreShow fewer
- Study of Single and Multiple Ascending Doses of CM551 in Healthy ParticipantsOct 28, 2026NCT07900945
- Validation and Clinical Impact of GLIM Criteria in Patients With Inflammatory Bowel DiseaseOct 22, 2026NCT07888023
- Objective Disease Control and Treatment Strategies in Ulcerative ColitisOct 16, 2026NCT07877636
- Longitudinal Registry of Difficult-to-Treat Inflammatory Bowel DiseaseOct 16, 2026NCT07877649
- Oral Aeromonas sp. MTB Phage Therapy for Pouchitis in Patients With Ulcerative Colitis (UC)Oct 16, 2026NCT07878026
- Efficacy and Safety of TRA16 Administered Orally in Patients With Enteric Hyperoxaluria (EH).Oct 13, 2026NCT07871669
Studies
Recruiting first, then most recently updated. Showing 50 of 1,853. Browse all 1,853 → or search them.
- Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)RecruitingNCT06651281Phase 37 countries
- Longitudinal Immunophenotyping of Patients With Inflammatory Bowel DiseaseRecruitingNCT076195471 country
- Safety and Efficacy of a STOPping Strategy Versus Classical Maintenance Dose of JAK Inhibitors in Deep Remission Patients With Ulcerative ColitisNot yet recruitingNCT07718529Phase 41 country
- Microbiome-targeted Diet Therapy in Ulcerative ColitisRecruitingNCT07520461Not applicable1 country
- Nitazoxanide as Adjunct Therapy in Mild-to-Moderate Ulcerative ColitisRecruitingNCT07820046Phase 2/31 country
- Long-term Safety and Efficacy of Multiple Long-acting Antibodies Alone and in Combinations for IBDEnrolling by invitationNCT07652294Phase 224 countries
- Effects of Different Physical Activity Strategies on Disease Activity of IBD PatientsNot yet recruitingNCT07916493Not applicable
- MOdel-Informed Precision Dosing of Ustekinumab and VEdolizumab in Inflammatory Bowel DiseaseEnrolling by invitationNCT06788340Phase 41 country
- Ibd CAncer and seRious Infections in France (I-CARE 2)RecruitingNCT060895901 country
- Characterization of Colorectal Dysplasic Lesions and Stratification of Their Evolving Risk in Inflammatory Bowel Disease Patients: a Prospective, Observational and Multicenter StudyRecruitingNCT077194261 country
- An Open-label, DDI Study to Investigate the Effects of Duvakitug on the PK of Selected Cytochrome P450 SubstratesNot yet recruitingNCT07923383Phase 1
- Non-Invasive Biomarker Monitoring in UC on BiologicsNot yet recruitingNCT079203671 country
- A Sub Study to Investigate the Safety and Tolerability of Aletekitug in Participants With Moderate To Severe Ulcerative ColitisRecruitingNCT07747480Phase 11 country
- A Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Afimkibart (RO7790121) in Children With Moderately to Severely Active Ulcerative ColitisRecruitingNCT07158242Phase 39 countries
- Specific and Novel Approaches to Care of Inflammatory Bowel Disease During Pregnancy: the PREGO StudyRecruitingNCT07916727Not applicable1 country
- A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's DiseaseRecruitingNCT07483073Phase 210 countries
- LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:RecruitingNCT07186101Phase 217 countries
- Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b StudyRecruitingNCT06937086Phase 323 countries
- LY4268989 in Adults With Moderately to Severely Active Ulcerative ColitisRecruitingNCT07415044Phase 228 countries
- A Study to Assess the Long-Term Safety of Ustekinumab Versus Other Biologics in Patients With Crohn's Disease and Ulcerative ColitisRecruitingNCT043721081 country
- A Remotely Conducted Study to Assess Concentration of TREMFYA in Breast Milk of Lactating Women Who Are Receiving TREMFYA TherapeuticallyRecruitingNCT07654751Phase 41 country
- A Study to Observe Real-world Evidence of Guselkumab Treatment in Participants With Ulcerative Colitis and Crohn's Disease in the United Kingdom (UK)RecruitingNCT072422481 country
- A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative ColitisRecruitingNCT07577856Phase 333 countries
- Safety, Dosage, and Microbiome Engraftment Study of MGT-006 for Ulcerative Colitis (ROOT Study)RecruitingNCT07913347Phase 1/22 countries
- A Study of Guselkumab in Participants With Crohn's Disease and Ulcerative ColitisRecruitingNCT076063391 country
- A Long-term Extension (LTE) Study of Guselkumab in Pediatric ParticipantsRecruitingNCT06663332Phase 318 countries
- A Study to Generate Real-world Evidence of Guselkumab Effectiveness in Inflammatory Bowel Disease in GermanyRecruitingNCT071023681 country
- A Real-World Study of Guselkumab in Chinese Participants With Ulcerative ColitisRecruitingNCT073023601 country
- A Real-World Study of Guselkumab Persistence and Effectiveness in Participants With Crohn's Disease or Ulcerative ColitisNot yet recruitingNCT078487371 country
- A Study of Continued Use of Guselkumab in Participants With Crohn's Disease and Ulcerative Colitis in Real World SettingNot yet recruitingNCT07746765
- Aquamin® for Prevention of Ulcerative Colitis J-Pouch-associate Intestinal InflammationRecruitingNCT07501078Phase 21 country
- ALPCO Calprotectin CLIA Assay - Measurement of Calprotectin Levels in Human StoolRecruitingNCT068105181 country
- Study of XmAb942 in Healthy Participants and Participants With Ulcerative ColitisRecruitingNCT06619990Phase 1/219 countries
- Study Evaluating ISM5411 Administered Orally to Subjects With Active Ulcerative Colitis (BETHESDA)RecruitingNCT07265570Phase 21 country
- INSIGHT-IBD Pragmatic StudyEnrolling by invitationNCT07686757Phase 41 country
- Efficacy of Upadacitinib Re-induction Therapy in Patients With Ulcerative Colitis Who Lost Response to 30 mg Maintenance DoseNot yet recruitingNCT07700446Phase 4
- A Study to Investigate the Safety and Tolerability of Multiple Study Interventions in Participants With Moderate to Severe Ulcerative ColitisRecruitingNCT07747467Phase 11 country
- Bacillus Probiotic Spores in Supporting the Treatment of Chronic Inflammatory Bowel DiseaseRecruitingNCT07799428Not applicable1 country
- A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community SettingRecruitingNCT06581328Phase 41 country
- A Study of AC-101 Tablets in Patients With Ulcerative ColitisRecruitingNCT07755241Phase 21 country
- Study of Single and Multiple Ascending Doses of CM551 in Healthy ParticipantsNot yet recruitingNCT07900945Phase 11 country
- A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)RecruitingNCT06979336Phase 215 countries
- Robotic Inflammatory Bowel Disease Development, Learning and Efficacy StudyRecruitingNCT065794431 country
- A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative ColitisRecruitingNCT05287126Phase 25 countries
- Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative ColitisRecruitingNCT07697456Phase 25 countries
- A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative ColitisRecruitingNCT07071519Phase 316 countries
- A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative ColitisRecruitingNCT07012395Phase 235 countries
- An Observational Study of Etrasimod in Adult Patients With Moderate to Severe Ulcerative ColitisRecruitingNCT063986261 country
- Objective Disease Control and Treatment Strategies in Ulcerative ColitisNot yet recruitingNCT07877636
- Longitudinal Registry of Difficult-to-Treat Inflammatory Bowel DiseaseNot yet recruitingNCT07877649